Profile data is unavailable for this security.
About the company
IOL Chemicals and Pharmaceuticals Limited is engaged in manufacturing and selling of pharmaceutical and chemical products. The Company operates through two segments: Chemical, and Pharmaceutical. The Chemical segment produces and sells Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride, Mono Chloro Acetic Acid, Para Amino Phenol (PAP), and others. The Pharmaceutical segment produces and sells various active pharma ingredients (API) include Ibuprofen, Metformin, Fenofibrate, Lamotrigine, Clopidogrel Bisulphate, Pantoprazole, Gabapentin, Paracetamol, and others. Its API product portfolio includes Ibuprofen, Metformin HCL, Pantoprazole Sodium, Clopidogrel Bisulphate (Form II), Lamotrigine, Losartan Potassium, Levetiracetam, Paracetamol, Fenofibrate (Micronised), and Gabapentin. Its Specialty Chemical division includes Ethyl Acetate, and Acetic Anhydride. Its Ethyl Acetate is used in industries like flexible packaging, pharmaceuticals, ink, food processing, pesticides, and paint industry.
- Revenue in INR (TTM)20.72bn
- Net income in INR1.19bn
- Incorporated1986
- Employees2.78k
- LocationIOL Chemicals and Pharmaceuticals Ltd85, Industrial Area, 'A',LUDHIANA 141003IndiaIND
- Phone+91 1 612225531
- Fax+91 1 612608784
- Websitehttp://www.iolcp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 13.88bn | 48.00 | 63.11 | 15.99 | 51.67 | 6.53 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 1.98bn | -242.34m | 14.72bn | 445.00 | -- | -- | 3,152.02 | 7.43 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 15.29bn | 1.03k | 64.24 | 7.75 | 53.59 | 6.74 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| JG Chemicals Ltd | 7.57bn | 550.05m | 16.18bn | 56.00 | 27.97 | 3.71 | 25.94 | 2.14 | 14.77 | 14.77 | 202.34 | 111.33 | -- | -- | -- | 135,230,700.00 | -- | -- | -- | -- | 17.29 | -- | 7.56 | -- | 11.46 | -- | 0.0281 | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Sigachi Industries Ltd | 4.36bn | 660.99m | 16.60bn | 991.00 | 29.53 | 3.52 | 21.35 | 3.81 | 1.69 | 1.69 | 11.11 | 14.15 | 0.6266 | 3.01 | 3.27 | 4,396,491.00 | 9.36 | 14.77 | 13.25 | 19.57 | 50.50 | 50.30 | 14.93 | 14.92 | 1.39 | 6.47 | 0.2576 | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Syncom Formulations (India) Ltd | 3.29bn | 331.47m | 18.97bn | 802.00 | 49.71 | 6.05 | 49.28 | 5.76 | 0.406 | 0.406 | 3.49 | 3.34 | 0.8485 | 6.21 | 3.62 | 4,105,761.00 | 8.54 | 7.50 | 10.99 | 10.23 | 38.49 | 34.10 | 10.07 | 9.38 | 4.09 | 12.05 | 0.0435 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Beta Drugs Ltd | 3.35bn | 410.00m | 19.37bn | 371.00 | 47.25 | 10.71 | 37.95 | 5.79 | 42.65 | 42.65 | 348.21 | 188.13 | 1.26 | 4.04 | 3.74 | 9,022,873.00 | 15.42 | 15.10 | 23.35 | 22.23 | 39.95 | 39.77 | 12.25 | 12.38 | 1.59 | 17.06 | 0.0953 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Windlas Biotech Ltd | 6.96bn | 612.28m | 20.04bn | 1.15k | 32.84 | 4.25 | 24.79 | 2.88 | 29.20 | 29.20 | 331.88 | 225.63 | 1.06 | 6.07 | 4.43 | 6,028,180.00 | 9.30 | -- | 13.64 | -- | 37.52 | -- | 8.80 | -- | 1.61 | 30.61 | 0.0388 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 20.62bn | 2.78k | 17.39 | -- | 11.15 | 0.9953 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Hester Biosciences Ltd | 3.12bn | 234.69m | 20.73bn | 642.00 | 85.90 | 6.87 | 49.22 | 6.64 | 28.37 | 28.37 | 368.62 | 354.81 | 0.4617 | 1.22 | 3.23 | 4,862,882.00 | 3.89 | 6.15 | 4.91 | 7.69 | 71.13 | 66.64 | 8.42 | 12.83 | 1.22 | 2.85 | 0.4371 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Amrutanjan Health Care Ltd | 4.38bn | 475.20m | 20.92bn | 635.00 | 44.07 | 7.03 | 38.83 | 4.78 | 16.43 | 16.43 | 151.37 | 103.00 | 1.19 | 6.89 | 12.85 | 6,893,025.00 | 12.88 | 16.22 | 16.48 | 20.12 | 50.03 | 53.09 | 10.86 | 13.23 | 3.62 | 217.88 | 0.0074 | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| SMS Pharmaceuticals Ltd | 7.68bn | 593.38m | 21.20bn | 1.20k | 35.63 | 3.76 | 23.17 | 2.76 | 7.03 | 7.03 | 91.03 | 66.57 | 0.7278 | 1.81 | 4.18 | 6,420,048.00 | 5.55 | 5.43 | 8.40 | 7.33 | 30.10 | 33.30 | 7.62 | 7.87 | 0.7104 | 4.54 | 0.3361 | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Panacea Biotec Ltd | 5.50bn | -148.63m | 24.15bn | 1.15k | -- | 2.90 | 120.96 | 4.39 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Themis Medicare Ltd | 4.20bn | 529.90m | 26.34bn | 1.54k | 49.76 | 6.39 | 41.16 | 6.27 | 5.75 | 5.75 | 45.63 | 44.76 | 0.7306 | 2.39 | 2.22 | 2,727,670.00 | 9.21 | 11.12 | 12.57 | 16.46 | 64.64 | 60.32 | 12.61 | 14.96 | 1.56 | -- | 0.1651 | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Indoco Remedies Ltd | 17.73bn | 320.40m | 28.04bn | 5.93k | 91.21 | 2.57 | 20.57 | 1.58 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
Data as of Nov 21 2024. Currency figures normalised to IOL Chemicals and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
2.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| PineBridge Investments Asia Ltd.as of 30 Jun 2024 | 731.56k | 1.25% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 473.05k | 0.81% |
| Mellon Investments Corp.as of 07 Nov 2024 | 189.28k | 0.32% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 45.41k | 0.08% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 36.99k | 0.06% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 31.31k | 0.05% |
| DFA Australia Ltd.as of 30 Sep 2024 | 6.48k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 507.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Oct 2024 | 312.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
